Skip to content

Drug interactions

Eluxadoline + Repaglinide

Severity: Moderate

Eluxadoline and Repaglinide: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Repaglinide is an OATP1B1 inhibitor and may raise eluxadoline exposure, increasing its adverse effects such as constipation, nausea and pancreatitis risk. Eluxadoline labeling recommends a reduced dose with OATP1B1 inhibitors.

What this interaction means in plain words

Eluxadoline and Repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Eluxadoline belongs to Gastrointestinal Tract; Repaglinide belongs to Endocrine.

Evidence level: Moderate

Why it happens

Repaglinide inhibits OATP1B1-mediated hepatic uptake of eluxadoline.

What to do

Reduce eluxadoline to 75 mg twice daily during coadministration and monitor for gastrointestinal and pancreatic adverse effects.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Eluxadoline and Repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Eluxadoline with Repaglinide?

MediHelp rates the interaction as moderate. Eluxadoline and Repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Repaglinide is an OATP1B1 inhibitor and may raise eluxadoline exposure, increasing its adverse effects such as constipation, nausea and pancreatitis risk. Eluxadoline labeling recommends a reduced dose with OATP1B1 inhibitors.

How serious is the interaction between Eluxadoline and Repaglinide?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Reduce eluxadoline to 75 mg twice daily during coadministration and monitor for gastrointestinal and pancreatic adverse effects.

What other medicines interact with Repaglinide?

MediHelp also lists interactions of Repaglinide with, for example, Gemfibrozil, Clarithromycin, Clopidogrel. The full list is on the Repaglinide page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in